Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
2.715
+0.005 (0.18%)
Jun 8, 2026, 2:16 PM EDT - Market open
Altimmune Revenue
Altimmune had revenue of $36.00K in the twelve months ending March 31, 2026, up 80.00% year-over-year. In the year 2025, Altimmune had annual revenue of $41.00K with 105.00% growth.
Revenue (ttm)
$36.00K
Revenue Growth
+80.00%
P/S Ratio
14,693.60
Revenue / Employee
$632
Employees
57
Market Cap
528.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.00K | 21.00K | 105.00% |
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | - |
| Dec 31, 2022 | -68.00K | -4.48M | - |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | 5.80M | -4.53M | -43.85% |
| Dec 31, 2018 | 10.33M | -407.10K | -3.79% |
| Dec 31, 2017 | 10.74M | 7.50M | 231.82% |
| Dec 31, 2016 | 3.24M | -7.40M | -69.59% |
| Dec 31, 2015 | 10.64M | 450.50K | 4.42% |
| Dec 31, 2014 | 10.19M | -7.72M | -43.11% |
| Dec 31, 2013 | 17.91M | -7.26M | -28.85% |
| Dec 31, 2012 | 25.18M | 909.60K | 3.75% |
| Dec 31, 2011 | 24.27M | 3.27M | 15.59% |
| Dec 31, 2010 | 20.99M | -6.56M | -23.80% |
| Dec 31, 2009 | 27.55M | -5.36M | -16.29% |
| Dec 31, 2008 | 32.91M | 18.27M | 124.75% |
| Dec 31, 2007 | 14.64M | 12.98M | 780.39% |
| Dec 31, 2006 | 1.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 299.77M |
| Valneva SE | 180.25M |
| Ginkgo Bioworks Holdings | 151.40M |
| XOMA Royalty | 48.56M |
| Prime Medicine | 4.03M |
| ProKidney | 889.00K |
ALT News
- 4 days ago - Altimmune Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 11 days ago - Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide - TheFly
- 11 days ago - Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 - GlobeNewsWire
- 12 days ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 - GlobeNewsWire
- 21 days ago - Altimmune price target lowered to $20 from $25 at H.C. Wainwright - TheFly
- 25 days ago - Altimmune Slides: Corporate presentation - Filings
- 25 days ago - Altimmune price target lowered to $11 from $14 at Citizens - TheFly